ASML HOLDING 1 657.800 € (-1,09 %) 
L'OREAL 380.100 € (-1,91 %) ESSILORLUXOTTICA 173.550 € (-2,28 %) AXA 42.500 € (+0,24 %) DANONE 65.060 € (-0,97 %) ADYEN 875.800 € (-3,10 %) HERMES INTL 1 721.500 € (-2,35 %) PROSUS 38.215 € (-2,24 %) AIRBUS 189.420 € (-1,31 %) SAINT GOBAIN 78.260 € (-1,88 %) BNP PARIBAS ACT.A 101.580 € (+0,47 %) 
AMA CORPORATION 0.130 € (-7,14 %) LEGRAND 151.500 € (-0,49 %) SANOFI 74.140 € (+1,09 %) NEXANS 158.800 € (+2,85 %) BOLLORE 5.515 € (+2,13 %) OSE IMMUNO 3.492 € (-2,57 %) CEGEDIM 11.460 € (+0,53 %) CREDIT AGRICOLE 17.695 € (+0,43 %) AIR LIQUIDE 164.160 € (-1,77 %) LVMH 499.250 € (-1,16 %) VALLOUREC 22.480 € (+1,44 %) PERNOD RICARD 64.140 € (+0,44 %) CARREFOUR 15.550 € (+0,81 %) ASM INTERNATIONAL 1 066.500 € (-0,37 %) NN GROUP 74.880 € (+1,08 %) AHOLD DEL 34.610 € (+0,26 %) MEDINCELL 24.080 € (-1,71 %) CARVOLIX 3.540 € (-1,67 %) BE SEMICONDUCTOR 309.800 € (-2,52 %) RELX 27.520 € (+1,10 %) RIBER 12.980 € (+0,78 %) VOPAK 45.540 € (+0,98 %) 
ARCELORMITTAL SA 54.980 € (-1,58 %) VALNEVA 2.305 € (+0,70 %) BIOMERIEUX 69.000 € (+2,15 %) ALTEN 57.600 € (+0,79 %) AALBERTS NV 39.960 € (-1,09 %) GOLD BY GOLD 4.160 € (-0,24 %) VERALLIA 19.340 € (-0,72 %) TOTALENERGIES 71.070 € (+1,04 %) CIECHARGEURSINVEST 8.260 € (0,00 %) DASSAULT AVIATION 302.000 € (+0,27 %) BENETEAU 6.550 € (-1,21 %) KPN KON 4.354 € (+0,76 %) LHYFE 2.000 € (0,00 %) TECHNIP ENERGIES 35.660 € (-1,44 %) SOCIETE GENERALE 77.670 € (-0,49 %) ACCOR 48.300 € (-1,15 %) BUREAU VERITAS 26.010 € (-0,76 %) BAM GROEP KON 12.420 € (-0,56 %) AMG 36.980 € (+0,54 %) WORLDLINE 10.424 € (-2,05 %) ARKEMA 58.100 € (+0,87 %) SOITEC 118.500 € (+1,72 %) EUTELSAT COMMUNIC. 2.423 € (+2,02 %) PHILIPS KON 23.500 € (0,00 %) SHELL PLC 34.535 € (+0,95 %) DBV TECHNOLOGIES 2.832 € (+0,43 %) MAUREL ET PROM 8.065 € (+1,57 %) |
15/06/2026 23:00
BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARESPress release BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARESParis (France) and Cambridge (Massachusetts, U.S.), June 15, 2026, at 11:00 p.m CET. – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces the temporary suspension of the trading of its shares by Euronext. This suspension results from the non-publication of the annual financial report for the fiscal year ended December 31, 2025, due to an operational delay in the preparation of the financial statements. The report will be published following certification of the accounts by the statutory auditors, which is expected no later than the end of July 2026. Trading of Biophytis shares on Euronext Growth Paris was suspended on June 15, 2026, and is expected to resume following the publication of the annual financial report. The Company will keep the market informed of the date on which trading will resume. * * * About BiophytisBiophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com. Biophytis ContactInvestor relations Media relations Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière